The United States Patent Trial and Appeal Board invalidated, Wednesday, two of the patents protecting Copaxone, Teva Pharmaceutical Industries multiple sclerosis drug, which generates $4 billion a year, 20 percent of its revenue. The Israeli generic-drug giant said it will appeal..
The agency is scheduled to issue a final decision on a third drug by September 1, according to Dutch drug company Mylan NV, which petitioned for the patents to be reviewed. The board has rejected a Mylan petition to invalidate a fourth patent, though a second petition against the patent is pending. Shares of Teva fell as much as 6 percent on the New York Stock Exchange before the stock recovered some losses and closed about 3 percent lower.